Modified factor VIII cDNA

Details Modified factor VIII cDNA Modified factor VIII cDNA

2001-06-15

2004-10-05

Guzo, David (Department: 1636)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S325000, C435S320100, C435S455000, C536S023100, C536S023500

Reexamination Certificate

active

06800461

ABSTRACT:

This invention is directed to a modified Factor VIII cDNA and its use for the improvement of the Factor VIII production.
Factor VII (FVIII) is a plasma coagulation cofactor implicated in the activation of Factor X (FX). A decrease in the presence or activity of Factor VIII in blood stream leads to hemophilia A. The level of the decrease in Factor VIII activity is directly proportional to the severity of the disease (Foster and T. S., 1989; Kaufman, 1992; Vlot et al., 1998). The current treatment of hemophilia A consists of the replacement of the missing protein by plasma-derived or recombinant FVIII. Recombinant FVIII is produced in CHO or BHK cells after selection of the best producing clones and amplification of the FVIII cDNA copy number.
Several studies have stressed the low FVIII production level in different cellular systems: Biosynthesis of FVIII was shown to be regulated in at least three different levels. First, among the FVIII cDNA sequence two nucleotides stretches, localized in the A2 coding domain, were demonstrated to act as transcriptional silencers (Fallaux et al, 1996; Hoeben et al., 1995; Koeberl et al., 1995; Lynch et al., 1993). Second, FVIII protein synthesis is tightly regulated by several reticulum endoplasmic chaperones (BiP; Calreticulin; Calnexin; ERGIC-53). Many of these interactions retain FVIII in the cell and direct it through the cellular degradation machinery (Dorner et al., 1987; Nichols et al., 1998; Pipe et al., 1998). Third, once secreted FVIII is sensitive to protease degradation and needs to be protected by von Willebrand Factor (vWF) (Kaufman et al., 1989).
It is therefore a problem to develop improved processes which result in higher yields of FVIII. The present invention offers a solution to this problem by a modified FVIII cDNA.


REFERENCES:
patent: 5112950 (1992-05-01), Meulien et al.
patent: 6271025 (2001-08-01), Negrier et al.
patent: 6399587 (2002-06-01), Mehtali et al.
patent: 0 197 901 (1986-10-01), None
patent: 0 295 597 (1988-12-01), None
patent: 0 303 540 (1989-02-01), None
patent: 1 038 959 (2000-09-01), None
patent: 1 048 726 (2000-10-01), None
patent: 1 231 220 (2002-08-01), None
patent: WO 87/04187 (1987-07-01), None
patent: WO 88/00831 (1988-02-01), None
patent: WO 92/16557 (1992-10-01), None
Kurachi et al. Role of Intron I in expression of the human Factor IX gene. J. Biol. Chem. 2705276-5281, 1995.*
Abstract, WO 98/55639 (Dec. 10, 1998).
Andersson, L.O. et al., “Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma,”Proc. Natl. Acad. Sci. USA, vol. 83: 2979-2983, (1986).
Brinkhaus et al., “Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs,”Proc. Natl. Acad. Sci. USA, vol. 82: 8752-8756 (1985).
Buchman et al., “Comparison of Intron-Dependent and Intron-Independent Gene Expression,”Molecular and Cellular Biology, vol. 8(10):4395-4405 (1988).
Burke et al., “The Functional Domains of Coagulation Factor VIII:C*,”J. Biol. Chem., vol. 261: 12574-12578 (1986).
Connelly et al., “High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice”,Human Gene Therapy, vol. 7(2):183-195 (1996).
Derwent abstract of EP 0 295 597 A2.
Derwent abstract of EP 0 303 540 B1.
Eaton et al., “Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule,”American Chemical Society, vol. 25(26): 8343-8347 (1986).
Fallaux, F.J. et al., “The Human Clotting Factor VIII cDNA Contains an Autonomously Replicating Sequence Consensus-and Matrix Attachment Region-like Sequence that Binds a Nuclear Factor, Represses Heterologous Gene Expression, and Mediates the Transcriptional Effects of Sodium Butyrate,”Mol. Cell. Biol., vol. 16: 4264-4272 (1996).
Foster, P.A., et al., “Factor VIII Structure and Function,”Blood Reviews, vol. 3: 180-191(1989).
Gitschier, J. et al., “Characterization of the human factor VIII gene,”Nature, vol. 312: 326-330 (1984).
Hoeben, R.C. et al., “Toward gene therapy in haemophilia: A retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells,”Thrombosis and Haemostasis, vol. 67(3): 341-345 (1992).
Kaufman, R.J. “Biological Regulation of Factor-VIII Activity,”Ann. Rev. of Medicine, vol. 43: 325-339 (1992).
Kaufman, R.J. et al., “Effects of von Willebrand Factor Coexpression on the Synthesis and Secretion of Factor VIII in Chinese Hamster Ovary Cells,”Mol. Cell. Biol., vol. 9: 1233-1242 (1989).
Kim et al., “Heterologous Introns Enhanced Expression of Human Lactoferrin cDNA in Mouse Mammary Epithelial Cells,”J. Biochem. Mol. Biol., vol. 28(1):57-61 (1995).
Koeberl, D.D., et al., “Sequence within the Coding Regions of Clotting Factor VIII and CFTR Block Transcription Elongation,”Human Gene Therapy, vol. 6: 469-479 (1995).
Laemmli, U.K. “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,”Nature, vol. 227: 680-685 (1970).
Lagner et al., “Synthesis of Biologically Active Deletion Mutants of Human Factor VIII:C,”Behring Inst. Mitt., vol. 82:16-25 (1988).
Lind, Peter et al., “Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules Construction and Biochemical Characterization,”Bur. J. Biochemistry, vol. 232:19-27 (1995).
Lynch, C.M., et al., “Sequences in the Coding Region of Clotting Factor VIII Act as Dominant Inhibitors of RNA Accumulation and Protein Production,”Human Gene Therapy, vol. 4: 8537-8544 (1998).
Meulien et al., “A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII,”Protein Engineering, vol. 2(4):301-306 (1988).
Nichols, W.C., et al., “Mutations in the ER-Golgi Intermediate Compartment Protein ERGIC-53 cause Combined Deficiency of Coagulation Factors V and VIII,”Cell, vol. 93: 61-70 (1998).
Pavirani et al., “Two Independent Domains of Factor VIII Co-Expressed Using Recombinant Vaccinia Viruses Have Procoagulant Activity,”Biochem. Biophys. Res. Comm., vol. 145 (1):234-240 (1987).
Pipe, S.W. et al., “Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones Calnexin and Calreticulin,”J. Biol. Chem., vol. 273: 8537-8544 (1998).
Pittman, D.D. et al., “Biochemical, Immunological, and In Vivo Function Characterization of B-domain-Deleted Factor VIII,”Blood, vol. 81: 2925-2935 (1993).
Plantier J.L. et al., “A factor VIII minigene comprising the truncated intron I of factor IX highly improves the in vitro production of factor VIII,”Thrombosis and Haemosiasis, vol. 86(2):596-603 (2001).
Plantier, J.L., et al., “A Combination of Truncated Factor IX Intron 1 Highly Improves FVIII Production,”Blood, vol. 94., No. 10, Supp. 1, Part 1: 454a, Forty-first Annual Meeting of the American Society of Hematology. Abstract No. 2021 (1999).
Roberts, Harold R., “Molecular Biology of Hemophila B,”Thrombosis and Haemostasis, vol. 70: 1-9 (1993).
Sarver et al., “Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector,”DNA, vol. 6(6):553-564 (1987).
Toole, J.J., et al., “A Large Region (≈95 kDa) of Human Factor VIII is Dispensable for In Vitro Procoagulant Activity,”Proc. Nat'l. Acad. Sci. USA, vol. 83:5939-5942 (1986).
Toole, J.J. et al., “Molecular cloning of a cDNA encoding human antihaemophilic factor,”Nature, vol. 312: 342-347 (1984).
Vehar, G.A. et al., “Structure of human factor VIII,”Nature, vol. 312:. 337-342 (1984).
Vlot, A.J. et al., “Factor VIII and von Willebrand Factor,”Thromb Haemost.vol. 79: 456-465 (1998).
Wood et al., “Expression of active human factor VIII from recombinant DNA clones,”Nature, 312:330-337 (1984).

Affiliated with

Also associated with

Rating

Modified factor VIII cDNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified factor VIII cDNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified factor VIII cDNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3298352